CDX2 and neoplasm: We find a homogeneous distribution of genetic mutations, yet strongly diverging numbers of DNA copy numbers in multiple genes implicated in tumour progression and therapy response, such as CDX2, CARD11, MMP9 and BRCA2. This work indicates that regional differences in gene copy numbers are an important aspect of tumour heterogeneity in CRC.